1	Intrinsic and effective severity of COVID-19 cases infected with the ancestral
2	strain and Omicron BA.2 variant in Hong Kong
3	
4	Jessica Y. Wong ¹ , Justin K. Cheung ¹ , Yun Lin ¹ , Helen S. Bond ¹ , Eric H. Y. Lau ^{1,2} ,
5	Dennis K. M. Ip ¹ , Benjamin J. Cowling ^{1,2} , Peng Wu ^{1,2}
6	
7	Affiliations:
8	1. WHO Collaborating Centre for Infectious Disease Epidemiology and Control,
9	School of Public Health, Li Ka Shing Faculty of Medicine, The University of
10	Hong Kong, Hong Kong Special Administrative Region, China
11	2. Laboratory of Data Discovery for Health Limited, Hong Kong Science and
12	Technology Park, New Territories, Hong Kong Special Administrative
13	Region, China
14	
15	Corresponding author:
16	Benjamin J. Cowling, School of Public Health, Li Ka Shing Faculty of Medicine, The
17	University of Hong Kong, 7 Sassoon Road, Pokfulam, Hong Kong
18	Tel: +852 3917 6711; Email: <u>bcowling@hku.hk</u>
19	
20	Word count (abstract): 280
21	Word count (main text): 3,142
22	
23	Keywords: COVID-19, intrinsic, severity, SARS-CoV-2, Omicron
24	

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

25 ABSTRACT

26	Background: Understanding severity of infections with SARS-CoV-2 and its variants
27	is crucial to inform public health measures. Here we used COVID-19 patient data
28	from Hong Kong to characterise the severity profile of COVID-19 and to examine
29	factors associated with fatality of infection.
30	Methods: Time-varying and age-specific effective severity measured by case-
31	hospitalization risk and hospitalization risk was estimated with all individual COVID-
32	19 case data collected in Hong Kong from 23 January 2020 through to 26 October
33	2022 over six epidemic waves, in comparison with estimates of influenza
34	A(H1N1)pdm09 during the 2009 pandemic. The intrinsic severity of Omicron BA.2
35	was compared with the estimate for the ancestral strain with the data from
36	unvaccinated patients without previous infections. Factors potentially associated with
37	the fatality risk of hospitalized Omicron patients were also examined.
38	Results: With 32,222 COVID-19 hospitalizations and 9,669 deaths confirmed over 6
39	epidemic waves in Hong Kong, the time-varying hospitalization fatality risk
40	dramatically increased from below 10% before the largest fifth wave of Omicron
41	BA.2, to 41% during the peak of the fifth wave when hospital resources were severely
42	constrained. The age-specific fatality risk in unvaccinated hospitalized Omicron cases
43	was comparable to the estimates for unvaccinated cases with the ancestral strain.
44	During epidemics predominated by Omicron BA.2, the highest fatality risk was
45	amongst unvaccinated patients aged ≥ 80 years and the risk was inversely associated
46	with the number of vaccination doses received.
47	Conclusions: Omicron has comparable intrinsic severity to the ancestral Wuhan
48	strain although the effective severity is substantially lower in Omicron cases due to
49	vaccination. With a moderate-to-high coverage of vaccination, hospitalized COVID-

- 50 19 patients caused by Omicron subvariants appeared to have similar age-specific risks
- 51 of fatality to patients hospitalized with influenza A(H1N1)pdm09.

53 INTRODUCTION

54	Hong Kong successfully suppressed four epidemic waves of infection with the
55	ancestral strain of SARS-CoV-2 during the first two years of the pandemic, with
56	12,631 RT-PCR confirmed infections (1.7 cases per 1,000 population) and 213 deaths
57	reported by the end of 2021 [1]. Serologic data confirmed that below 1% of the
58	population had been infected over the same period [2]. However, a large community
59	epidemic caused by Omicron subvariant peaked in early March 2022 [3, 4], leading to
60	over 1.1 million confirmed cases (164.3 cases per 1,000 population) and 9,157 deaths.
61	Two COVID-19 vaccines, the inactivated (CoronaVac, Sinovac) and the mRNA
62	vaccine (BNT162b2, BioNTech/Fosun Pharma), were made available in Hong Kong
63	in early 2021. As of 1 January 2022, approximately 70% of the Hong Kong
64	population aged 3 years or above had received at least two doses of vaccination [5]
65	although vaccination uptake was lower in older adults [6].
66	
67	The severity profile of SARS-CoV-2 infections is one of the major determinants for
68	assessing potential health impact of epidemics on a population [7]. One measure of
69	infection severity is the "hospitalization fatality risk" (HFR). This describes the risk
70	of death among hospitalized cases with laboratory-confirmed SARS-CoV-2 infections
71	[8], which comprise a smaller and more homogenous subgroup of infected individuals
72	requiring admission for healthcare than all laboratory-confirmed cases. A related
73	measure of severity is the risk of hospitalization among all cases, i.e. the case

74 hospitalization risk (CHR). The CHR multiplied by the HFR should approximate the

75 fatality risk among all confirmed cases, i.e. the case fatality risk (CFR).

76

77	Here, we analyzed detailed individual case data from Hong Kong, to quantify the
78	overall and temporal patterns of COVID-19 severity in Hong Kong, and identify
79	factors associated with mortality among hospitalized COVID-19 cases. Because
80	Omicron BA.2 was the first strain of COVID-19 to circulate widely in Hong Kong we
81	also aim to estimate the intrinsic severity of SARS-CoV-2 variants using data on
82	infections in unvaccinated individuals.
83	
84	METHODS
85	Sources of data
86	Individual data on all laboratory-confirmed COVID-19 cases infected locally in Hong
87	Kong from 23 January 2020 to 26 October 2022 were obtained from the Hospital
88	Authority and Centre for Health Protection [5]. RT-PCR was used exclusively for
89	confirmation of COVID-19 until 25 February 2022 when a positive rapid antigen test
90	was also accepted as laboratory confirmation [9]. From 7 June 2022 onwards,
91	individuals reporting a positive rapid antigen test were issued with a compulsory
92	testing notice and required to undergo PCR testing within the next two days, and any
93	individuals with negative PCR tests were not counted as COVID-19 cases [10].
94	Demographic, clinical and epidemiological information was collected for individual
95	patients, including age, sex, comorbidities, oxygen saturation levels measured by the
96	pulse oximetry in hospital, severity outcome at discharge, vaccination status, use of
97	nirmatrelvir-ritonavir (Paxlovid) or molnupiravir, residence in care homes for the
98	elderly (RCHE), dates of COVID-19 vaccination for individual doses, laboratory
99	confirmation, hospital admission, death and discharge. Our study received ethical
100	approval from the Institutional Review Board of the University of Hong Kong.
101	

102	Up to 14 February 2022, all laboratory-confirmed COVID-19 cases in Hong Kong
103	were admitted into hospital for isolation, and from 15 February onwards, given the
104	rapidly increasing number of COVID-19 cases and limited hospital capacity, only
105	those requiring hospital medical care were admitted. In this study, we defined
106	hospitalized cases as COVID-19 patients confirmed by RT-PCR or rapid antigen test
107	and clinically classified as a severe, critically ill or fatal case based on assessment of
108	oxygen desaturation, use of medication and procedure, and information such as A&E
109	departmental visits and ICU admissions from clinical records, i.e., cases requiring
110	healthcare in hospital. Detailed information on severity classification of COVID-19
111	cases is shown in Appendix. We used data on patients with laboratory confirmation of
112	SARS-CoV-2 infection obtained in the 14 days preceding hospital admission in the
113	analysis on HFR, and used data on all patients tested positive for SARS-CoV-2 either
114	by RT-PCR or rapid antigen test in the analysis of CHR.
115	
116	For comparison, we used the data obtained from the Hospital Authority on all
117	individual patients with laboratory-confirmed A(H1N1)pdm09 infection identified
118	during May-December 2009 when influenza A(H1N1)pdm09 virus was first
119	circulating and monovalent H1N1pdm09 vaccines had not been widely used in Hong
120	Kong [11], including age, sex, dates of admission into hospital and intensive care unit,
121	dates of receipt of oseltamivir treatment and death.
122	

123 Statistical analysis

124 All COVID-19 cases confirmed in each epidemic wave or period of wave were

125 examined in terms of age, sex, severity status and delay distributions. We estimated

126 the effective severity of COVID-19 with the case hospitalization risk (CHR) and the

127 hospitalization fatality risk (HFR). The weekly CHR was estimated as the reported 128 weekly number of hospitalized COVID-19 cases divided by the weekly total number 129 of confirmed cases allowing for a mean lag of 3 days from case notification to 130 hospitalization. The weekly HFR was calculated as the proportion of fatal cases (eventual number of deaths occurred by the end of the study period) among all 131 132 hospitalized cases admitted in a particular week. We estimated the CHR and HFR in 133 time periods during which at least 35 confirmed cases and at least 15 confirmed 134 hospitalized cases were reported per week in 4 or more consecutive weeks in order to 135 provide effective comparisons between different epidemic waves avoiding large 136 uncertainties from very small case numbers. We also estimated the age-stratified CHR 137 and HFR with the same data for five age groups: <18 years, 18-44 years, 45-64 years, 65-79 years and \geq 80 years for each pre-defined epidemic wave over the study period. 138 139 140 The data on COVID-19 cases without vaccination in Hong Kong before widespread 141 of Omicron in wave 5 particularly in older adults with a low vaccination coverage allowed us to assess the intrinsic severity of SARS-CoV-2. We determined the HFR 142 143 among hospitalized cases at age of <65, 65-79 and \geq 80 years with complete 144 comorbidity information. We also estimated the age-specific relative risk in 145 logarithmic scale as the HFR in the early part of the fifth wave divided by the HFR in 146 waves 1-4. Cases included in the analysis were confirmed before 14 February 2022 147 without receiving any dose of COVID-19 vaccination more than 14 days prior to 148 confirmation of COVID-19 and without a recorded previous infection. We applied 149 logistic regression models to the daily unvaccinated hospitalized COVID-19 cases 150 confirmed in the early part of the fifth wave and earlier epidemic waves to examine 151 factors potentially associated with the intrinsic fatality risk of SARS-CoV-2. In the

regression model, we adjusted for age group, gender, comorbidities, and RCHE status.
Age-specific HFR estimates were also obtained for unvaccinated cases confirmed in
wave 6 for comparison.

155

156 Omicron BA.2 caused the largest epidemic wave 5 in Hong Kong since January 2022 157 extending to wave 6 in May-August 2022. We estimated the HFR with cases 158 confirmed during the period predominated by Omicron BA.2 by vaccine dose and 159 type to illustrate the potential protection provided by COVID-19 vaccination. We 160 determined the vaccine-related relative risk in logarithmic scale for the three age 161 groups as the HFR among cases with a specific vaccine dose combination divided by the HFR among cases that did not receive any dose of COVID-19 vaccination. We 162 performed a similar regression analysis to compare the risk of mortality for patients 163 164 confirmed in wave 5. In the model, we further adjusted for vaccination type and dose, 165 antiviral use and period of case confirmation. 166 167 We estimated the HFR of influenza A(H1N1)pdm09 with cases confirmed in 2009 as 168 the division of cumulative number of deaths by the cumulative number of laboratory-

169 confirmed hospitalized cases who were treated with oseltamivir or admitted into an

170 intensive care unit during hospital stay. All analyses were conducted with R version

171 4.1.0 (R Foundation for Statistical Computing, Austria).

172

173 **RESULTS**

174 The periods of spread of SARS-CoV-2 in Hong Kong can be divided into six

175 epidemic waves, including four prior to the widespread uptake of vaccines, a large

176 fifth wave predominated by Omicron BA.2 between January and May 2022, and a

177	sixth wave driven by Omicron BA.2 and BA.4/5 subvariants (Figure 1). A total of
178	1,979, 22,805 and 7,438 COVID-19 cases were hospitalized for treatment in waves 1-
179	4, wave 5 and wave 6, respectively. Of all the deaths, 88.8% (8,586/9,669) occurred
180	within 28 days of confirmation, and 98.7% (9,548/9,669) occurred within 90 days. In
181	the peak period of wave 5 (wave 5b, between 14 February and 29 April 2022), 0.8%
182	(4/491), 9.6% (62/646), 22.7% (568/2,504), 31.5% (1,887/5,986) and 46.0%
183	(5,832/12,667) of the hospitalized cases were fatal in age groups <18, 18-44, 45-64,
184	65-79 and \geq 80 years, respectively (Appendix). The median admission-to-death
185	intervals decreased from 18 days in waves 1-4 to 8 days in the peak period of wave 5.
186	The median admission-to-discharge intervals were very similar, decreasing from 17
187	days to 11 days in waves 1-4 to peak period of wave 5 respectively.
188	
189	From January 2020 to October 2022, the smoothed estimate of weekly CHR gradually
190	decreased from 15.9% at the end of wave 3 to 10.5% at the end of wave 4 (Figure 1).
191	In comparison, the weekly HFR estimates similarly declined from 18.1% (95% CI:
192	9.2%, 27.1%) to 8.3% (95% CI: 3.0%, 13.5%) during the same time period. In waves
193	5-6, CHR estimates were relatively stable at low levels (around 0.7%) while the HFR
194	estimates increased substantially from 3.4% (95% CI: 0.0%, 7.7%) in late January
195	2022, peaked at 41.3% (95% CI: 37.9%, 44.8%) in early March before declining to
196	12.2% (95% CI: 7.9%, 16.4%) by the end of October.
197	
198	The highest hospitalization risk was observed in cases aged \geq 65 years (8.2%, 95% CI:
199	8.1%, 8.3%) in wave 5, similar to cases at the same age (5.2%, 95% CI: 5.0%, 5.3%)
200	in wave 6 (Figure 2). The CHR of cases aged 45-64 and \geq 65 years in waves 1-4
201	appeared to be approximately six times the risk in those at the same age in wave 5

202	(50.0%, 95% CI: 47.8%, 52.4%). The fatality risk of hospitalized cases aged ≥ 65
203	years (41.1%, 95% CI: 40.4%, 41.8%) in wave 5 doubled the risk in individuals in the
204	same age group in waves 1-4 (19.7%, 95% CI: 17.2%, 22.4%) and wave 6 (17.0%,
205	95% CI: 16.0%, 18.0%), and the pattern remained the same for 45-64 years. The HFR
206	estimates were comparable between hospitalized influenza A(H1N1)pdm09 cases in
207	2009 and COVID-19 cases confirmed during wave 6 (Figure 2B).
208	
209	There were 22,604 COVID-19 patients hospitalized in wave 5 between 31 December
210	2021 and 22 May 2022 (Table 1). After accounting for factors associated with
211	mortality, individuals with at least one dose of BNT162b2 or CoronaVac had
212	significantly lower odds of mortality than those unvaccinated, with the lowest odds
213	observed in individuals with three doses of BNT162b2 (OR: 0.31, 95% CI: 0.18,
214	0.49). In addition to at an older age (65-79 years and \geq 80 years vs 45-64 years), being
215	an RCHE resident, having malignant neoplasms or cardiovascular diseases, and
216	confirmed during the peak period were associated with an increased odds of mortality.
217	Female cases, at a younger age or being treated with antivirals (Paxlovid and
218	molnupiravir) had a lower odds of being fatal.
219	
220	There were 1,974 and 186 unvaccinated COVID-19 patients hospitalized in waves 1-4
221	and wave 5a, respectively, included in our analysis of intrinsic severity (Table 2). The
222	age-specific estimates of HFR for cases \geq 80 years (39.7%, 95% CI: 28.5%, 51.9%)
223	and 65-79 years (19.3%, 95% CI: 10.0%, 31.9%) confirmed in wave 5a were similar
224	to the corresponding estimates of 39.0% (95% CI: 33.1%, 45.0%) and 11.4% (95%
225	CI: 9.0%, 14.1%) for cases in waves 1-4 (Figure 3). No significant differences in

226 fatality risk were observed for hospitalized cases in wave 5a relative to those in waves

227	1-4 across all age groups. After accounting for factors potentially associated with
228	mortality, hospitalized cases confirmed in wave 5a showed a similar fatality risk to
229	the cases from waves 1-4 (OR: 1.08, 95% CI: 0.61, 1.83). The odds of mortality were
230	significantly higher in individuals aged 65-79 years (OR: 4.80, 95% CI: 2.94, 8.26)
231	and ≥80 years (OR: 20.81, 95% CI: 12.66, 35.95) than in individuals aged 45-64
232	years.

233

234 Among cases hospitalized in non-peak periods of wave 5 and the first half of wave 6 235 (wave 5a from 31 December 2021 to 13 February 2022, and waves 5c and 6a from 30 236 April to 30 August 2022) with Omicron BA.2 predominant, mean estimates of the 237 fatality risk were largely higher in unvaccinated patients and those receiving fewer 238 doses of vaccine in age groups <65, 65-79 and \geq 80 years except for those with two 239 doses of BNT162b2 showing a higher mean estimate of HFR than cases receiving one dose only or 2-dose CoronaVac among cases aged <65 years (Appendix). Relative 240 241 risk estimates showed that vaccination had a considerable effect in reducing fatality 242 risk, especially for those who received at least two doses of CoronaVac or BNT162b2 243 in ≥ 80 years.

244

245 **DISCUSSION**

246 Infections with the Omicron variant were originally recognized as being milder than

with other variants [12] although it has been challenging to determine whether the

attenuated severity of Omicron infections is due to an increased competency in

- 249 infecting and replicating in the upper respiratory tract [13], or acquired immunity
- 250 from previous infection and/or vaccination in affected populations [14]. Our analysis
- of intrinsic severity was conducted based on fatalities in unvaccinated COVID-19

252 patients admitted into hospital for treatment in Hong Kong during epidemic waves 253 predominated by the ancestral Wuhan strain or Omicron BA.2 during January 2020 – 254 February 2022 with a relatively low population coverage of COVID-19 vaccines 255 especially in the elderly. The estimates of HFR indicated that Omicron BA.2 had a 256 similar intrinsic severity to infections with the ancestral strain (Table 2). 257 Comparatively lower fatality risk in hospitalized COVID-19 patients infected with the 258 ancestral strain or Omicron than Delta were reported in unvaccinated individuals from 259 the UK and the US [15-18]. 260 261 In estimation of fatality risk of COVID-19, using HFR was perhaps less biased than 262 CFR using the number of confirmed cases as the denominator because the 263 ascertainment of cases in need of hospital care would be relatively homogenous

264 particularly in places with adequate capacity in case identification and healthcare

265 services. Non-pharmaceutical and pharmaceutical measures have been widely used to

slow down the transmission of COVID-19 to "flatten the curve" particularly in order

to reduce the peak demand for hospital services. However, when healthcare services

are under severe pressure often due to rapidly spread of infection, both hospitalized

269 patient numbers and outcomes could be heavily affected, which would impact the

270 HFR. Extreme pressure on hospital resources during large surges in COVID

271 hospitalizations has been estimated to cause significantly increased COVID mortality

rates in some locations, including Italy, the United States, England, and Brazil [19-

273 23]. We estimated that the estimated HFR increased by a factor of three during the

274 peak of the Omicron BA.2 wave in Hong Kong (Table 1). Therefore, in our analysis,

we defined hospitalized COVID-19 patients with a set of pre-determined criteria

276 (Appendix) to allow for comparison of HFR estimates across epidemic waves.

0		
7	/	/

278	It is well established that the severity of COVID-19 increases substantially with age
279	[24] as also shown in our age-specific estimates of HFR. The age-specific HFRs in
280	our study indicated that a much higher fatality risk in adult cases hospitalized in the
281	epidemic wave of Omicron than earlier waves, different from previous studies
282	showing reduction in disease severity [25, 26]. This likely resulted from a higher
283	proportion of older adults infected in wave 5 (Appendix) within a short time period
284	leading to less optimal clinical outcomes in patients with constrained healthcare
285	capacity [27].
286	
287	By the end of wave 4 in December 2021, only around 12,000 COVID-19 cases were
288	confirmed in Hong Kong [28], with a low vaccine coverage with two or more doses of
289	either CoronaVac or BNT162b2 particularly in those \geq 80 years of age [5]. We had a
290	unique opportunity to investigate the intrinsic HFR for the Omicron in comparison
291	with the ancestral strain by making use of fatality information collected from
292	unvaccinated individuals, and at the same time to explore the potential protection
293	against death from vaccines using vaccinated COVID-19 cases without a recorded
294	infection history. Our estimation overcame some challenges in understanding the
295	intrinsic severity of Omicron [14] while further virological and immunological
296	evidence is needed to back up the observations from epidemiologic studies. However,
297	we were only able to estimate intrinsic severity of Omicron BA.2 here because
298	COVID-19 had not circulated widely in Hong Kong prior to 2022.
299	
300	The estimated lower risk of death among hospitalized COVID-19 cases was indicated

301 for vaccinees with any dose of the vaccine in comparison to the unvaccinated

302	inpatients (Table 1), largely comparable with our previous findings on the
303	effectiveness of COVID-19 vaccines against severe COVID-19 [5]. Furthermore, the
304	potential protection provided by Paxlovid or molnupiravir demonstrated in a local
305	territory-wide cohort of COVID-19 inpatients and outpatients during the Omicron
306	BA.2 wave [29, 30] perhaps could explain the lower HFR estimated in wave 6
307	compared with wave 5c (Appendix) considering a gradually expanding use of the
308	antivirals since mid-March 2022 in Hong Kong [31].

309

310 There are several limitations in our study. First, temporal comparison of severity 311 estimates over epidemic waves might be affected by varied case definitions and 312 practices in hospital admission over time [32]. We classified the severity status of 313 laboratory-confirmed COVID-19 cases based on objective measures as much as 314 possible, and defined hospitalized cases consistently throughout the study period, 315 aiming to minimize bias in the denominator of HFR, and enable valid comparisons of 316 severity measures across waves and patient groups. Second, fatality risk might differ 317 in patients admitted due to COVID-19 and those hospitalized for other reasons and 318 infected later with COVID-19, which might affect estimates of the HFR [25]. We 319 limited our analysis on HFR to hospitalized patients with the confirmation 14 days 320 earlier than the admission to exclude patients who might be infected in hospitals. 321 Third, clinical outcomes were unknown for 1.6% of the patients who were still in 322 hospital by the end of the study. The exact estimates of HFR for wave 6b might 323 change slightly if final outcomes of these patients are obtained although we do not 324 anticipate this would change our study conclusions given the small number of patients 325 involved.

326

327	In conclusion, similar intrinsic severity of Omicron to the ancestral strain and the
328	protection conferred by vaccines against fatality risk in hospitalized COVID-19
329	patients highlighted that vaccination is critically important in reducing COVID-19
330	associated health impact. Continued monitoring of epidemiologic characteristics of
331	new variants and subvariants of SARS-CoV-2 is crucial, including assessment of
332	effective severity. As testing and reporting cases in the community reduces in
333	frequency, but hospital testing likely continues in many locations, data on the HFR
334	may provide a metric that is easier to evaluate over time than CFR. Serologic data on
335	patterns in infections over time, if available, could provide a more complete picture of
336	changes over time in severity.
337	

339 ACKNOWLEDGMENTS

- 340 The authors thank Julie Au for technical support.
- 341

342 FUNDING

- 343 This project was supported by a commissioned grant from the Health and Medical
- Research Fund of the Hong Kong SAR Government (grant no. CID-HKU2-13), and
- the Collaborative Research Scheme (project no. C7123-20G) of the Research Grants
- 346 Council of the Hong Kong SAR Government. BJC is supported by the RGC Senior
- 347 Research Fellow Scheme grant (HKU SRFS2021-7S03) from the Research Grants
- 348 Council of the Hong Kong Special Administrative Region, China. The funding bodies
- had no role in the design of the study, the collection, analysis, and interpretation of
- 350 data, or writing of the manuscript.
- 351

352 AUTHOR CONTRIBUTIONS

- 353 The study was conceived by BJC and PW. JYW, PW and JKC analyzed the data.
- 354 JYW wrote the first draft of the manuscript. All authors provided critical review and

355 revision of the text and approved the final version.

356

357 DATA SHARING STATEMENT

- 358 Restrictions apply to the availability of these data. The hospitalization and mortality
- data are available for access with the permission from the Hospital Authority and the
- 360 Census and Statistics Department of Hong Kong.

362 **DECLARATION OF INTERESTS**

- 363 BJC consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon, Moderna,
- 364 Pfizer, Roche and Sanofi Pasteur. The other authors report no other potential conflicts
- 365 of interest.

366 **REFERENCES**

367	1.	Cowling BJ, Ali ST, Ng TWY, et al. Impact assessment of non-
368		pharmaceutical interventions against coronavirus disease 2019 and influenza
369		in Hong Kong: an observational study. Lancet Public Health 2020;5(5):e279-
370		e88.
371	2.	To KK, Cheng VC, Cai JP, et al. Seroprevalence of SARS-CoV-2 in Hong
372		Kong and in residents evacuated from Hubei province, China: a multicohort
373		study. Lancet Microbe 2020;1(3):e111-e8.
374	3.	Mefsin YM, Chen D, Bond HS, et al. Epidemiology of Infections with SARS-
375		CoV-2 Omicron BA.2 Variant, Hong Kong, January-March 2022. Emerg
376		Infect Dis 2022;28(9):1856-8.
377	4.	Viana R, Moyo S, Amoako DG, et al. Rapid epidemic expansion of the SARS-
378		CoV-2 Omicron variant in southern Africa. Nature 2022;603(7902):679-86.
379	5.	McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of one, two,
380		and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong
381		Kong: a population-based observational study. Lancet Infect Dis
382		2022 ;22(10):1435-43.
383	6.	Xiao J, Cheung JK, Wu P, et al. Temporal changes in factors associated with
384		COVID-19 vaccine hesitancy and uptake among adults in Hong Kong: Serial
385		cross-sectional surveys. Lancet Reg Health West Pac 2022;23:100441.
386	7.	Wong JY, Wu P, Nishiura H, et al. Infection fatality risk of the pandemic
387		A(H1N1)2009 virus in Hong Kong. Am J Epidemiol 2013;177(8):834-40.
388	8.	Wong JY, Kelly H, Cheung CM, et al. Hospitalization Fatality Risk of
389		Influenza A(H1N1)pdm09: A Systematic Review and Meta-Analysis. Am J
390		<i>Epidemiol</i> 2015 ;182(4):294-301.

- 3919.The Government of the Hong Kong Special Administrative Region. Selecting
- 392 and using rapid antigen tests.
- 393 (https://www.info.gov.hk/gia/general/202202/27/P2022022600796.htm).
- 394 (Accessed 6 February 2023).
- 395 10. The Government of the Hong Kong Special Administrative Region. CHP
- 396 investigates 82 confirmed and 132 asymptomatic additional SARS-CoV-2
- 397 virus cases with 17 cases pending status by nucleic acid tests as well as
- 398 verified 258 cases tested positive by rapid antigen tests.
- 399 (https://www.info.gov.hk/gia/general/202206/07/P2022060700716.htm).
- 400 (Accessed 30 December 2022).
- 401 11. Wong JY, Wu P, Lau EH, et al. Real-time estimation of the hospitalization
- 402 fatality risk of influenza A(H1N1)pdm09 in Hong Kong. *Epidemiol Infect*403 **2016**;144(8):1579-83.
- 40412.Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity405of the SARS-CoV-2 omicron variant in South Africa: a data linkage study.
- 406 *Lancet* **2022**;399(10323):437-46.
- 407 13. Hui KPY, Ng KC, Ho JCW, et al. Replication of SARS-CoV-2 Omicron BA.2
- 408 variant in ex vivo cultures of the human upper and lower respiratory tract.
- 409 *EBioMedicine* **2022**;83:104232.
- 410 14. Bhattacharyya RP, Hanage WP. Challenges in Inferring Intrinsic Severity of
 411 the SARS-CoV-2 Omicron Variant. *N Engl J Med* 2022;386(7):e14.
- 412 15. Bast E, Tang F, Dahn J, et al. Increased risk of hospitalisation and death with
 413 the delta variant in the USA. *Lancet Infect Dis* 2021;21(12):1629-30.
- Robinson ML, Morris CP, Betz JF, et al. Impact of SARS-CoV-2 variants on
 inpatient clinical outcome. *Clin Infect Dis* 2022 (Online ahead of print).

416	17.	Nyberg T, Ferguson NM, Nash SG, et al. Comparative analysis of the risks of
417		hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529)
418		and delta (B.1.617.2) variants in England: a cohort study. Lancet
419		2022 ;399(10332):1303-12.
420	18.	Greene SK, Levin-Rector A, Kyaw NTT, et al. Comparative hospitalization
421		risk for SARS-CoV-2 Omicron and Delta variant infections, by variant
422		predominance periods and patient-level sequencing results, New York City,
423		August 2021-January 2022. Influenza Other Respir Viruses
424		2023 ;17(1):e13062.
425	19.	Volpato S, Landi F, Incalzi RA. A Frail Health Care System for an Old
426		Population: Lesson form the COVID-19 Outbreak in Italy. J Gerontol A Biol
427		<i>Sci Med Sci</i> 2020 ;75(9):e126-e7.
428	20.	Dang A, Thakker R, Li S, et al. Hospitalizations and Mortality From Non-
429		SARS-CoV-2 Causes Among Medicare Beneficiaries at US Hospitals During
430		the SARS-CoV-2 Pandemic. JAMA Netw Open 2022;5(3):e221754.
431	21.	Gray WK, Navaratnam AV, Day J, et al. COVID-19 hospital activity and in-
432		hospital mortality during the first and second waves of the pandemic in
433		England: an observational study. <i>Thorax</i> 2022 ;77(11):1113-20.
434	22.	Brizzi A, Whittaker C, Servo LMS, et al. Author Correction: Spatial and
435		temporal fluctuations in COVID-19 fatality rates in Brazilian hospitals. Nat
436		<i>Med</i> 2022 ;28(7):1509.
437	23.	Janke AT, Mei H, Rothenberg C, et al. Analysis of Hospital Resource
438		Availability and COVID-19 Mortality Across the United States. J Hosp Med
439		2021 ;16(4):211-4.

440	24.	Levin AT, Hanage WP, Owusu-Boaitey N, et al. Assessing the age specificity
441		of infection fatality rates for COVID-19: systematic review, meta-analysis,
442		and public policy implications. <i>Eur J Epidemiol</i> 2020 ;35(12):1123-38.
443	25.	Reichert E, Schaeffer B, Gantt S, et al. Methods for early characterisation of
444		the severity and dynamics of SARS-CoV-2 variants: a population-based time
445		series analysis in South Africa. Lancet Microbe 2022;3(10):e753-e61.
446	26.	Jassat W, Abdool Karim SS, Mudara C, et al. Clinical severity of COVID-19
447		in patients admitted to hospital during the omicron wave in South Africa: a
448		retrospective observational study. Lancet Glob Health 2022;10(7):e961-e9.
449	27.	Ko YK, Murayama H, Yamasaki L, et al. Age-Dependent Effects of COVID-
450		19 Vaccine and of Healthcare Burden on COVID-19 Deaths, Tokyo, Japan.
451		Emerg Infect Dis 2022;28(9):1777-84.
452	28.	The Government of the Hong Kong Special Administrative Region. CHP
453		investigates 12 additional confirmed cases of COVID-19 and 11 additional
454		Omicron cases.
455		(https://www.info.gov.hk/gia/general/202112/30/P2021123000612.htm).
456		(Accessed 20 January 2023).
457	29.	Wong CKH, Au ICH, Lau KTK, et al. Real-world effectiveness of
458		molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation,
459		and in-hospital outcomes among community-dwelling, ambulatory patients
460		with confirmed SARS-CoV-2 infection during the omicron wave in Hong
461		Kong: an observational study. Lancet 2022;400(10359):1213-22.
462	30.	Wong CKH, Au ICH, Lau KTK, et al. Real-world effectiveness of early
463		molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19
464		without supplemental oxygen requirement on admission during Hong Kong's

465		omicron BA.2 wave: a retrospective cohort study. <i>Lancet Infect Dis</i>
466		2022 ;22(12):1681-93.
467	31.	The Government of the Hong Kong Special Administrative Region. First
468		shipment of COVID-19 oral drug Paxlovid distributed to HA for application
469		(with photos).
470		(https://www.info.gov.hk/gia/general/202203/15/P2022031500280.htm).
471		(Accessed 20 January 2023).
472	32.	Tsang TK, Wu P, Lin Y, et al. Effect of changing case definitions for COVID-
473		19 on the epidemic curve and transmission parameters in mainland China: a
474		modelling study. Lancet Public Health 2020;5(5):e289-e96.
475		

Table 1. Logistic regression of risk factors of mortality among hospitalized local COVID-19 cases

confirmed in wave 5 predominated by Omicron subvariants from 31 December 2021 to 22 May 2022.

	Sample size (n)	Deaths (%) ^a	Non-discharged cases (%) ^a	Odds ratio (95% CI) ^b
Age, years				
<18	508	5/508 (1.0)	0/508 (0.0)	0.03 (0.01, 0.07)
18-44	683	61/683 (8.9)	23/683 (3.4)	0.45 (0.33, 0.59)
45-64	2,574	573/2,574 (22.3)	68/2,574 (2.6)	1.00
65-79	6,091	1,899/6,091 (31.2)	28/6,091 (0.5)	1.50 (1.34, 1.68)
≥80	12,748	5,850/12,748 (45.9)	21/12,748 (0.2)	2.88 (2.59, 3.21)
Gender				
Male	12,845	5,016/12,845 (39.1)	85/12,845 (0.7)	1.00
Female	9,759	3,372/9,759 (34.6)	55/9,759 (0.6)	0.76 (0.72, 0.81)
RCHE resident				
No	12,622	3,997/12,622 (31.7)	125/12,622 (1.0)	1.00
Yes	9,982	4,391/9,982 (44.0)	15/9,982 (0.2)	1.17 (1.10, 1.24)
<i>Comorbidities</i> ^c				
Diabetes	5,119	1,959/5,119 (38.3)	20/5,119 (0.4)	0.96 (0.90, 1.03)
Malignant neoplasms	2,135	997/2,135 (46.7)	8/2,135 (0.4)	2.03 (1.84, 2.24)
Cardiovascular diseases	9,987	4,420/9,987 (44.3)	47/9,987 (0.5)	1.47 (1.39, 1.56)
Vaccination combinations				
Unvaccinated	14,180	6,047/14,180 (42.6)	102/14,180 (0.7)	1.00
One dose BNT162b2	453	127/453 (28.0)	2/453 (0.4)	0.67 (0.54, 0.84)
One dose CoronaVac	3,681	1,200/3,681 (32.6)	10/3,681 (0.3)	0.71 (0.65, 0.77)
Two doses BNT162b2	955	194/955 (20.3)	7/955 (0.7)	0.53 (0.44, 0.63)
Two doses CoronaVac	2,794	738/2,794 (26.4)	18/2,794 (0.6)	0.58 (0.53, 0.64)
Three doses BNT162b2	171	20/171 (11.7)	0/171 (0.0)	0.31 (0.18, 0.49)
Three doses CoronaVac	311	47/311 (15.1)	1/311 (0.3)	0.36 (0.26, 0.49)
Two doses CoronaVac				
with BNT162b2 booster	59	15/59 (25.4)	0/59 (0.0)	0.71 (0.37, 1.29)

Antiviral use

None	18,972	7,448/18,972 (39.3)	113/18,972 (0.6)	1.00
Paxlovid	734	117/734 (15.9)	4/734 (0.5)	0.39 (0.32, 0.48)
Molnupiravir	2,898	823/2,898 (28.4)	23/2,898 (0.8)	0.62 (0.56, 0.68)
Time of confirmation				
Wave 5a: 31/12 - 13/2 ^d	282	47/282 (16.7)	0/282 (0.0)	1.00
Wave 5b (by week):				
14/2 - 20/2	1,081	356/1,081 (32.9)	7/1,081 (0.6)	1.92 (1.36, 2.77)
21/2 - 27/2 (Peak)	2,509	1,128/2,509 (45.0)	15/2,509 (0.6)	3.05 (2.19, 4.32)
28/2 - 6/3	4,550	2,018/4,550 (44.4)	38/4,550 (0.8)	2.96 (2.14, 4.18)
7/3 - 13/3	4,783	1,913/4,783 (40.0)	50/4,783 (1.0)	2.49 (1.79, 3.51)
14/3 - 20/3	4,479	1,565/4,479 (34.9)	19/4,479 (0.4)	2.10 (1.52, 2.97)
21/3 - 27/3	2,222	671/2,222 (30.2)	3/2,222 (0.1)	1.93 (1.38, 2.74)
28/3 - 3/4	1,229	332/1,229 (27.0)	3/1,229 (0.2)	1.75 (1.24, 2.53)
4/4 - 10/4	590	156/590 (26.4)	3/590 (0.5)	1.80 (1.23, 2.66)
11/4 - 17/4	351	81/351 (23.1)	0/351 (0.0)	1.52 (1.00, 2.32)
18/4 - 24/4	191	46/191 (24.1)	0/191 (0.0)	1.74 (1.07, 2.82)
25/4 - 29/4	114	28/114 (24.6)	1/114 (0.9)	1.63 (0.93, 2.83)
Wave 5c: 30/4 – 22/5 ^d	223	47/223 (21.1)	1/223 (0.4)	1.47 (0.91, 2.35)

^a Proportions presented in the columns were defined as the number of events over the number of cases in each strata that were included in the analysis

^b Analysis was based on COVID-19 cases confirmed between 31/12/2021 and 22/5/2022, classified with severity of severe or above based on criteria outlined in the Appendix and with confirmation-to-admission delays of no more than 14 days (N=22,604) ^c Odds ratios were determined by comparing patients that have the listed comorbidities with patients that do not ^d Wave 5a (31/12/2021 - 13/2/2022); Wave 5b (14/2/2022 - 29/4/2022); Wave 5c (30/4/2022 - 22/5/2022)

Table 2. Logistic regression of risk factors of mortality among hospitalized local COVID-19 cases that did

not receive any dose of COVID-19 vaccine, waves 1-4 vs wave 5a.

Sample size (n)	Deaths (%) ^a	Non-discharged cases (%) ^a	Odds ratio (95% CI) ^b
45	0/45 (0.0)	0/45 (0.0)	0.00 (0.00, 0.00)
256	2/256 (0.8)	0/256 (0.0)	0.41 (0.06, 1.43)
806	19/806 (2.4)	1/806 (0.1)	1.00
708	85/708 (12.0)	0/708 (0.0)	4.80 (2.94, 8.26)
345	135/345 (39.1)	1/345 (0.3)	20.81 (12.66, 35.95)
1,222	146/1,222 (11.9)	2/1,222 (0.2)	1.00
938	95/938 (10.1)	0/938 (0.0)	0.68 (0.49, 0.92)
2,107	220/2,107 (10.4)	2/2,107 (0.1)	1.00
53	21/53 (39.6)	0/53 (0.0)	1.39 (0.63, 3.06)
1,493	85/1,493 (5.7)	2/1,493 (0.1)	1.00
667	156/667 (23.4)	0/667 (0.0)	2.89 (2.13, 3.95)
1,974	198/1,974 (10.0)	2/1,974 (0.1)	1.00
186	43/186 (23.1)	0/186 (0.0)	1.08 (0.61, 1.83)
	Sample size (n) 45 256 806 708 345 1,222 938 2,107 53 1,493 667 1,974 186	Sample size (n)Deaths (%) ^a 45 $0/45 (0.0)$ 256 $2/256 (0.8)$ 806 $19/806 (2.4)$ 708 $85/708 (12.0)$ 345 $135/345 (39.1)$ 1,222 $146/1,222 (11.9)$ 938 $95/938 (10.1)$ 2,107 $220/2,107 (10.4)$ 53 $21/53 (39.6)$ 1,493 $85/1,493 (5.7)$ 667 $156/667 (23.4)$ 1,974 $198/1,974 (10.0)$ 186 $43/186 (23.1)$	Sample size (n)Deaths (%)*Non-discharged cases (%)*45 $0/45 (0.0)$ $0/45 (0.0)$ 256 $2/256 (0.8)$ $0/256 (0.0)$ 806 $19/806 (2.4)$ $1/806 (0.1)$ 708 $85/708 (12.0)$ $0/708 (0.0)$ 345 $135/345 (39.1)$ $1/345 (0.3)$ 1,222 $146/1,222 (11.9)$ $2/1,222 (0.2)$ 938 $95/938 (10.1)$ $0/938 (0.0)$ 2,107 $220/2,107 (10.4)$ $2/2,107 (0.1)$ 53 $21/53 (39.6)$ $0/53 (0.0)$ 1,493 $85/1,493 (5.7)$ $2/1,493 (0.1)$ 667 $156/667 (23.4)$ $0/667 (0.0)$ 1,974 $198/1,974 (10.0)$ $2/1,974 (0.1)$ 186 $43/186 (23.1)$ $0/186 (0.0)$

Proportions presented in the columns were defined as the number of events over the number of cases in each strata that were

included in the analysis

^b Analysis was based on COVID-19 cases with dates of confirmation during Waves 1-4 or Wave 5a, classified with severity of

severe or above based on criteria outlined in the Appendix and with confirmation-to-admission delays of no more than 14 days

(N=2,160)

^c If patients have at least one of the following comorbidities: diabetes, malignant neoplasms and cardiovascular diseases

^d Waves 1-4 (23/1/2020 – 30/12/2021); Wave 5a (31/12/2021 – 13/2/2022)



Figure 1: Local COVID-19 cases and deaths, estimated case hospitalization risk and estimated hospitalization fatality risk in Hong Kong, 2020-2022. (A) Epidemic curve of daily local COVID-19 cases and deaths in wave 1 to wave 6. Cases were stratified by date of confirmation and deaths were stratified by date of death. (B) Weekly effective case hospitalization risk. (C) Weekly effective hospitalization fatality risk. Estimates in panels (B) and (C) were only plotted for weeks when \geq 35 local cases and \geq 15 hospitalized cases were confirmed for at least 4 consecutive weeks.



Figure 2: Age-specific estimates of the case hospitalization and hospitalization fatality risks for COVID-19 in waves 1-4, wave 5 and wave 6 in Hong Kong, compared with estimates of the hospitalization fatality risk for all hospitalized patients with pandemic influenza A(H1N1)pdm09 in 2009. (A) Case hospitalization risk in waves 1-4, 5 and 6 by age group, compared with pandemic influenza (H1N1)pdm09 in 2009. (B) Hospitalization fatality risk in waves 1-4, 5 and 6 by age group, compared with pandemic influenza (H1N1)pdm09 in 2009.



Figure 3: Age-specific estimates of the hospitalization fatality risk for COVID-19 among unvaccinated patients in Hong Kong by waves and relative risks of hospitalization fatality risk in wave 5a compared to waves 1-4. (A) Fatality risk among unvaccinated hospitalized local COVID-19 cases, in waves 1-4 compared with wave 5a by age group. (B) Relative risk of hospitalization fatality risk in wave 5a compared to waves 1-4 by age group.